These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 32999170)

  • 1. Effects of Concomitant Administration of Vonoprazan Fumarate on the Tacrolimus Blood Concentration in Kidney Transplant Recipients.
    Mei T; Noguchi H; Suetsugu K; Hisadome Y; Kaku K; Okabe Y; Masuda S; Nakamura M
    Biol Pharm Bull; 2020; 43(10):1600-1603. PubMed ID: 32999170
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Blood concentrations of tacrolimus upon conversion from rabeprazole to vonoprazan in renal transplant recipients: Correlation with cytochrome P450 gene polymorphisms.
    Watari S; Araki M; Matsumoto J; Yoshinaga K; Sekito T; Maruyama Y; Mitsui Y; Sadahira T; Kubota R; Nishimura S; Wada K; Kobayashi Y; Takeuchi H; Tanabe K; Kitagawa M; Morinaga H; Kitamura S; Sugiyama H; Ariyoshi N; Wada J; Watanabe M; Watanabe T; Nasu Y
    Drug Metab Pharmacokinet; 2021 Oct; 40():100407. PubMed ID: 34352707
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Effects of Vonoprazan Fumarate on the Tacrolimus Blood Concentration in Liver Transplant Recipients.
    Hidaka M; Soyama A; Hashizume J; Hara T; Matsunaga N; Matsushima H; Tanaka T; Hamada T; Imamura H; Adachi T; Kanetaka K; Ohyama K; Eguchi S
    Cancer Diagn Progn; 2022; 2(5):553-557. PubMed ID: 36060027
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nationwide conversion to generic tacrolimus in pediatric kidney transplant recipients.
    Naicker D; Reed PW; Ronaldson J; Kara T; Wong W; Prestidge C
    Pediatr Nephrol; 2017 Nov; 32(11):2125-2131. PubMed ID: 28660366
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Late conversion from tacrolimus to a belatacept-based immuno-suppression regime in kidney transplant recipients improves renal function, acid-base derangement and mineral-bone metabolism.
    Schulte K; Vollmer C; Klasen V; Bräsen JH; Püchel J; Borzikowsky C; Kunzendorf U; Feldkamp T
    J Nephrol; 2017 Aug; 30(4):607-615. PubMed ID: 28540602
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reduced C0 concentrations and increased dose requirements in renal allograft recipients converted to the novel once-daily tacrolimus formulation.
    de Jonge H; Kuypers DR; Verbeke K; Vanrenterghem Y
    Transplantation; 2010 Sep; 90(5):523-9. PubMed ID: 20592652
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Drug-Drug Interaction between Tacrolimus and Vonoprazan in Kidney Transplant Recipients.
    Suzuki Y; Yoshihashi T; Takahashi K; Furuya K; Ohkohchi N; Oda T; Homma M
    J Clin Med; 2021 Aug; 10(17):. PubMed ID: 34501411
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative clinical trial of the variability factors of the exposure indices used for the drug monitoring of two tacrolimus formulations in kidney transplant recipients.
    Marquet P; Albano L; Woillard JB; Rostaing L; Kamar N; Sakarovitch C; Gatault P; Buchler M; Charpentier B; Thervet E; Cassuto E
    Pharmacol Res; 2018 Mar; 129():84-94. PubMed ID: 29229354
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term Glomerular Filtration Rate and Kidney Disease: Improving Global Outcomes Stage Stability After Conversion to Once-Daily Tacrolimus in Kidney Transplant Recipients.
    Tinti F; Umbro I; Poli L; Cappoli A; Garofalo M; Bachetoni A; D'Alessandro MD; Lai S; Berloco PB; Mitterhofer AP
    Transplant Proc; 2019; 51(1):147-152. PubMed ID: 30655133
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Improved kidney graft function after conversion from twice daily tacrolimus to a once daily prolonged-release formulation.
    Kolonko A; Chudek J; Wiecek A
    Transplant Proc; 2011 Oct; 43(8):2950-3. PubMed ID: 21996198
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dynamic effects of CYP3A5 polymorphism on dose requirement and trough concentration of tacrolimus in renal transplant recipients.
    Chen P; Li J; Li J; Deng R; Fu Q; Chen J; Huang M; Chen X; Wang C
    J Clin Pharm Ther; 2017 Feb; 42(1):93-97. PubMed ID: 27885697
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lower variability of tacrolimus trough concentration after conversion from prograf to advagraf in stable kidney transplant recipients.
    Wu MJ; Cheng CY; Chen CH; Wu WP; Cheng CH; Yu DM; Chuang YW; Shu KH
    Transplantation; 2011 Sep; 92(6):648-52. PubMed ID: 21912349
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and Safety of Elective Conversion From Sotrastaurin (STN) to Tacrolimus (TAC) or Mycophenolate (MPS) in Stable Kidney Transplant Recipients.
    Hannun P; Felipe C; Ferreira A; Sandes-Freitas T; Cristelli M; Aguiar W; Franco M; Campos E; Gerbase de Lima M; Tedesco-Silva H; Medina-Pestana J
    Ther Drug Monit; 2016 Jun; 38(3):293-9. PubMed ID: 26919549
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tacrolimus dose and blood concentration variability in kidney transplant recipients undergoing conversion from twice daily to once daily modified release tacrolimus.
    Kurnatowska I; Krawczyk J; Oleksik T; Nowicki M
    Transplant Proc; 2011 Oct; 43(8):2954-6. PubMed ID: 21996199
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CYP3A4/5 polymorphisms affect the blood level of cyclosporine and tacrolimus in Chinese renal transplant recipients.
    Li DY; Teng RC; Zhu HJ; Fang Y
    Int J Clin Pharmacol Ther; 2013 Jun; 51(6):466-74. PubMed ID: 23557867
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Conversion From Twice-Daily to Once-Daily Tacrolimus in Stable Kidney Graft Recipients.
    Barreto P; Malheiro J; Vieira P; Pedroso S; Almeida M; Martins LS; Dias L; Henriques AC; Cabrita A
    Transplant Proc; 2016 Sep; 48(7):2276-2279. PubMed ID: 27742278
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pretransplant Tacrolimus Dose Requirements Predict Early Posttransplant Dose Requirements in Blood Group AB0-Incompatible Kidney Transplant Recipients.
    Shuker N; de Man FM; de Weerd AE; van Agteren M; Weimar W; Betjes MG; van Gelder T; Hesselink DA
    Ther Drug Monit; 2016 Apr; 38(2):217-22. PubMed ID: 26630539
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Conversion From a Twice-Daily to a Once-Daily Tacrolimus Formulation in Kidney Transplant Recipients.
    Kamińska D; Poznański P; Kuriata-Kordek M; Zielińska D; Mazanowska O; Kościelska-Kasprzak K; Krajewska M
    Transplant Proc; 2020 Oct; 52(8):2288-2293. PubMed ID: 32247597
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CYP3A5 polymorphisms and their effects on tacrolimus exposure in an ethnically diverse South African renal transplant population.
    Muller WK; Dandara C; Manning K; Mhandire D; Ensor J; Barday Z; Freercks R
    S Afr Med J; 2020 Jan; 110(2):159-166. PubMed ID: 32657689
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Distinct effects of omeprazole and rabeprazole on the tacrolimus blood concentration in a kidney transplant recipient.
    Takahashi K; Yano I; Fukuhara Y; Katsura T; Takahashi T; Ito N; Yamamoto S; Ogawa O; Inui K
    Drug Metab Pharmacokinet; 2007 Dec; 22(6):441-4. PubMed ID: 18159131
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.